1. Biomarkers and clinical outcomes in COPD: a systematic review and meta-analysis
- Author
-
Jilles M Fermont, Jacob M Marott, Katya L Masconi, Valéria Amorim Pires Di Lorenzo, Renata Ferrari, Hana Müllerová, Magnus T. Jensen, Angela M. Wood, Michael I. Polkey, Benjamin Waschki, Henrik Watz, Philipp Schuetz, Ian B. Wilkinson, Waschki, Benjamin [0000-0002-1070-3661], and Apollo - University of Cambridge Repository
- Subjects
Pulmonary and Respiratory Medicine ,medicine.medical_specialty ,Exacerbation ,Chronic Obstructive Pulmonary Disease ,Severity of Illness Index ,Pulmonary Disease, Chronic Obstructive ,Internal medicine ,Epidemiology ,Heart rate ,medicine ,Risk of mortality ,Humans ,copd epidemiology ,Pulse wave velocity ,COPD ,biology ,business.industry ,C-reactive protein ,Hemodynamics ,medicine.disease ,Respiratory Function Tests ,Meta-analysis ,biology.protein ,Exercise Test ,business ,Biomarkers - Abstract
BackgroundConventional measures to evaluate COPD may fail to capture systemic problems, particularly musculoskeletal weakness and cardiovascular disease. Identifying these manifestations and assessing their association with clinical outcomes (ie, mortality, exacerbation and COPD hospital admission) is of increasing clinical importance.ObjectiveTo assess associations between 6 min walk distance (6MWD), heart rate, fibrinogen, C reactive protein (CRP), white cell count (WCC), interleukins 6 and 8 (IL-6 and IL-8), tumour necrosis factor-alpha, quadriceps maximum voluntary contraction, sniff nasal inspiratory pressure, short physical performance battery, pulse wave velocity, carotid intima-media thickness and augmentation index and clinical outcomes in patients with stable COPD.MethodsWe systematically searched electronic databases (August 2018) and identified 61 studies, which were synthesised, including meta-analyses to estimate pooled HRs, following Meta-analysis of Observational Studies in Epidemiology (MOOSE) and Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.ResultsShorter 6MWD and elevated heart rate, fibrinogen, CRP and WCC were associated with higher risk of mortality. Pooled HRs were 0.80 (95% CI 0.73 to 0.89) per 50 m longer 6MWD, 1.10 (95% CI 1.02 to 1.18) per 10 bpm higher heart rate, 3.13 (95% CI 2.14 to 4.57) per twofold increase in fibrinogen, 1.17 (95% CI 1.06 to 1.28) per twofold increase in CRP and 2.07 (95% CI 1.29 to 3.31) per twofold increase in WCC. Shorter 6MWD and elevated fibrinogen and CRP were associated with exacerbation, and shorter 6MWD, higher heart rate, CRP and IL-6 were associated with hospitalisation. Few studies examined associations with musculoskeletal measures.ConclusionFindings suggest 6MWD, heart rate, CRP, fibrinogen and WCC are associated with clinical outcomes in patients with stable COPD. Use of musculoskeletal measures to assess outcomes in patients with COPD requires further investigation.Trial registration numberCRD42016052075.
- Published
- 2019